Titel der Studie:
Titel:
- M14-431: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
- M14-433: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies
- M14-430: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
Studiencode:
M14-431/ M14-433/ M14-430
EUDRACT-Nr.:
2017-001226-18
2017-001240-35
2017-001225-41
M14-431: https://clinicaltrials.gov/ct2/show/NCT03345836
M14-433: https://clinicaltrials.gov/ct2/show/NCT03345849
M14-430: https://clinicaltrials.gov/ct2/show/NCT03345823
Für weitere Informationen nehmen Sie bitte Kontakt mit unserem Studienzentrum auf.
Ansprechpartner im Studienzentrum Halle:
- PD Dr. med. Jens Walldorf
- Dr. med. Robin Greinert
Kontakt:
Klinisches Studienzentrum
Universitätsklinik und Poliklinik für Innere Medizin I
Martin-Luther-Universität Halle-Wittenberg /
Universitätsklinikum Halle (Saale)
Ernst-Grube-Straße 40
06120 Halle
Telefon: 0345 557 2668
Telefax: 0345 557 2253
email: studienzentrummedizin.uni-hallede